Rep. McAdams Backs Legislation to Speed Generic Medications to Market

December 4, 2019 by Dan McCue
Rep. McAdams Backs Legislation to Speed Generic Medications to Market
Rep. Ben McAdams

WASHINGTON – While some continue to merely talk about the need to rein in prescription drug prices, Rep. Ben McAdams, D-Utah, has actually taken action on bipartisan legislation to help lower the cost of often life-changing medications.

Along with fellow members of the moderate Blue Dog Coalition, McAdams supported and got the House to pass the CREATES Act and BLOCKING Act, bills aimed at helping generic drug makers bring their products to market more quickly while also lifting barriers to competition.

“Generic drugs are as effective as brand-name equivalents but often cost much less and that means substantial savings for patients,” McAdams told The Well News.

H.R. 965, the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act of 2019, prohibits pharmaceutical and biologic companies from engaging in anti-competitive conduct that blocks lower-cost generic drugs from entering the market.

Meanwhile, H.R. 938, the Bringing Low-cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019, rewards manufacturers for challenging weak patents and bringing new generic drugs to the market by challenging generic drugs from parking patents for an extended period of time.

Current law awards 180 days of exclusivity on the market to a drug manufacturer when they are the first to file a generic drug application with the FDA for a drug for which there is no generic.

This 180-day clock starts when the generic only starts to market their drug. This BLOCKING Act would start the 180-day clock once a second generic drug files their patent.

The Blue Dog Coalition last month called on Congress to take up these and other prescription drug pricing bills that they believe, if considered individually, could pass a Democratic-led House and a Republican-led Senate.

Among the other bills endorsed by the group is one that would prohibit the practice of “pay-for-delay,” in which brand name drug companies compensate generics to delay the entry of generic drugs into the market, and others that would mandate greater transparency for patients, doctors, employers, and other buyers, in regard to drug pricing and the factors that influence what they pay at the pharmacy counter.

“Congress must deliver results on lowering the cost of life saving drugs for American families,” Rep. McAdams said. “Every month we delay means more hardship and health problems for seniors covered under Medicare Part D. It’s wrong that they are not able to fill their prescriptions or take them as prescribed, because they aren’t affordable.”

McAdams said health care on one of the most frequent topics that his constituents ask him about during town halls back in his district.

“Utahns expect us to rise above partisan politics and not let that stop us from getting this important work done,” he said.  “The House has taken up a number of bipartisan proposals aimed at making the drug market more competitive and drugs more affordable, which we absolutely can and must get into law this Congress.

“But it’s clear that we also need to fix the system more broadly.,” McAdams continued. “We have bipartisan support between the House, Senate, and Administration to take big steps like slowing the rapid rise of drug prices.  Capping seniors’ out-of-pocket costs in Medicare Part D plans is one of my top priorities – we can’t let seniors living on fixed incomes skip their insulin, heart medications, or cancer treatments because drug prices rise exponentially, and they’re left on the hook for more and more.” 

The representative noted that Sen. Mike Lee, R-Utah,  has taken the lead on getting the CREATES Act through the Senate and said he believes the bill could actually make it to the president’s desk.

“Both sides need to stop playing politics with drug prices,” McAdams said. “I came to Congress as an independent voice for my district, not beholden to any particular party or ideology … [and] it is impractical to think that either Democrats or Republicans must demand ‘their way or the highway.’” 

“Frankly, with all the debate about divisive issues, we should take an opportunity to solve high drug prices, an issue that both parties agree on and have some common ground on the solutions,” he said.  “I continue working with my colleagues on both sides of the aisle to prove we can deliver results and fix a broken Congress. 

“Americans in Democratic and Republican districts across the country can’t wait for Congressional leaders to retreat to their partisan corners when instead we can make progress by working together,” McAdams said.

A+
a-
  • Ben McAdams
  • BLOCKING Act
  • Blue Dog Coalition
  • CREATES Act
  • prescription drug prices
  • Utah
  • In The News

    Health

    Voting

    Prescription Drugs

    Biden and Harris Team Up for Health Care Event in North Carolina

    WASHINGTON (AP) — President Joe Biden and Vice President Kamala Harris will promote their health care agenda on Tuesday in... Read More

    WASHINGTON (AP) — President Joe Biden and Vice President Kamala Harris will promote their health care agenda on Tuesday in North Carolina, a battleground state that Democrats hope to flip in their favor after falling short to Donald Trump in the last two presidential elections. Fourteen... Read More

    March 13, 2024
    by Dan McCue
    FDA Believed Poised to Approve First Med for a Serious Liver Disease

    WASHINGTON — The Food and Drug Administration appears poised to approve the first medicine developed specifically to treat the serious... Read More

    WASHINGTON — The Food and Drug Administration appears poised to approve the first medicine developed specifically to treat the serious liver disease known as MASH later this week.  Metabolic dysfunction-associated steatohepatitis -- formerly known as nonalcoholic steatohepatitis — is often associated with obesity. In patients who... Read More

    March 6, 2024
    by Dan McCue
    Health Care, Drug Prices to Be Cornerstone of State of the Union

    WASHINGTON — President Joe Biden’s plans to do more to lower prescription drug prices and ensure the nation’s health care... Read More

    WASHINGTON — President Joe Biden’s plans to do more to lower prescription drug prices and ensure the nation’s health care system works better for more Americans will be the centerpiece of his State of the Union address, the White House revealed Wednesday. In a conference call... Read More

    March 4, 2024
    by Dan McCue
    Judge Rules Against Drugmaker in Price Negotiation Lawsuit

    WILMINGTON, Del. — A federal judge in Delaware ruled against the pharmaceutical and biotech company AstraZeneca last Friday in a... Read More

    WILMINGTON, Del. — A federal judge in Delaware ruled against the pharmaceutical and biotech company AstraZeneca last Friday in a case challenging the constitutionality of Medicare’s new drug negotiation program. The case is one of several filed by the pharmaceutical industry and its allies and the... Read More

    March 1, 2024
    by Dan McCue
    CVS, Walgreens to Begin Selling Abortion Pills Later This Month

    WASHINGTON — The nation’s two largest pharmacy chains will start dispensing the abortion pill mifepristone in select states later this... Read More

    WASHINGTON — The nation’s two largest pharmacy chains will start dispensing the abortion pill mifepristone in select states later this month, just weeks before the Supreme Court is set to hear a case that could lead to its removal from the market. The decision by both... Read More

    February 22, 2024
    by Dan McCue
    House Democrats Launch Inquiry Into Nationwide Drug Shortages

    WASHINGTON — Democrats on the House Committee on Oversight and Accountability are pressing some of the nation's largest drug manufacturers... Read More

    WASHINGTON — Democrats on the House Committee on Oversight and Accountability are pressing some of the nation's largest drug manufacturers for answers on why there are still intermittent and repeated shortages of cancer meds and other drugs. Led by Rep. Jamie Raskin, D-Md., the ranking member... Read More

    News From The Well
    scroll top